Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021062371 - TNFRSF25-MEDIATED TREATMENTS OF IMMUNE DISEASES AND DISORDERS

Publication Number WO/2021/062371
Publication Date 01.04.2021
International Application No. PCT/US2020/053085
International Filing Date 28.09.2020
IPC
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C12N 5/0783 2010.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
0783T cells; NK cells; Progenitors of T or NK cells
C07K 14/52 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
52Cytokines; Lymphokines; Interferons
A61P 5/50 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
5Drugs for disorders of the endocrine system
48of the pancreatic hormones
50for increasing or potentiating the activity of insulin
CPC
A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies
A61P 5/50
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
5Drugs for disorders of the endocrine system
48of the pancreatic hormones
50for increasing or potentiating the activity of insulin
C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Applicants
  • PELICAN THERAPEUTICS, INC. [US]/[US]
  • THE GOVERNORS OF THE UNIVERSITY OF ALBERTA [CA]/[CA]
Inventors
  • SEAVEY, Matthew, M.
  • HUTCHINS, Jeff, T.
  • JASUJA, Rahul, R.
  • SHAPIRO, A.M., James
  • MARFIL-GARZA, Braulio, A.
Agents
  • ALTIERI, Stephen, L.
Priority Data
62/906,43826.09.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) TNFRSF25-MEDIATED TREATMENTS OF IMMUNE DISEASES AND DISORDERS
(FR) TRAITEMENTS À MÉDIATION PAR TNFRSF25 DE MALADIES ET DE TROUBLES IMMUNITAIRES
Abstract
(EN)
The present disclosure is directed to a method of treating or preventing diabetes, prediabetes, and/or glucose intolerance using TNF Receptor Superfamily Member 25 (TNFRSF25) agonistic antibody or antigen binding fragment thereof. The disclosure is also directed to methods for increasing graft survival and for treating or preventing graft-versus-host disease (GVHD) using TNFRSF25 agonistic antibody.
(FR)
La présente invention concerne une méthode de traitement ou de prévention du diabète, du prédiabète et/ou de l'intolérance au glucose à l'aide d'un anticorps agoniste de l'élément 25 de la superfamille des récepteurs du TNF (TNFRSF25) ou d'un fragment de liaison à l'antigène de celui-ci. La présente invention concerne également des méthodes pour augmenter la survie de greffe et pour traiter ou prévenir une réaction de greffe contre hôte (GVHD) à l'aide d'un anticorps agoniste de TNFRSF25.
Latest bibliographic data on file with the International Bureau